The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
Trial Was Stopped Due to Hepatotoxicity and Consequently TAK-994 Program Terminated for Further Development In…